10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M

10x Genomics, Inc.

2023-Q2 EPS reported -$0.97 revenue$281,104,000

Revenue $146.8M in Q2, +28% YoY from $114.6M.
Gross margin 68% vs 76% prior year, down on product mix from new launches.
Net loss $62.4M vs $64.5M YoY; stock-based compensation expense $45.7M.
Raises FY2023 revenue guidance to $600-620M from prior $590-610M, 16-20% growth.
Accelerated Xenium in situ platform momentum; launched Visium CytAssist Gene & Protein Expression assay.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported the second quarter ended June 30, 2023 results: revenue $146.8 million, net income Net loss was $62.4 million. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $146.8 million
Net income: Net loss was $62.4 million
Guidance: raised
Result: reported results

Exact text from the filing

Revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

10x Genomics, Inc. reported full year 2023 results: revenue $600 million to $620 million. Guidance raised.

Period: full year 2023
Revenue: $600 million to $620 million
Guidance: raised
Result: guidance update

Exact text from the filing

10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $600 million to $620 million, representing 16% to 20% growth over full year 2022.

View on SEC.gov

Browse all earnings releases →

10x Genomics, Inc. filing history →

Source: SEC EDGAR

accession 0001770787-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.